CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Britain Courts Anthropic Amid US Defense Department Dispute 
PORT WASHINGTON, N.Y., July 07, 2017 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health Products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Sal Guccione, president and CEO, will present at the Singular Summer Solstice Conference on Thursday, July 13, 2017 at 9:45AM ET.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact LHA Jody Burfening [email protected] (212) 838-3777
